SCHEMBL7047404

SCHEMBL7047404

CC[CH]CCCC(CC)CC

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP3A4 P08684 2/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20640391 0.88 ALDH1A1 (0.38) ALDH1A1TDP1CYP3A4TSHRL3MBTL1
SCHEMBL9214132 0.84 LMNA (0.45) ALDH1A1TDP1CYP3A4TSHRL3MBTL1
SCHEMBL10670984 0.83
SCHEMBL5810093 0.80 LMNA (0.45) ALDH1A1TDP1CYP3A4TSHRCA2
SCHEMBL10813417 0.78 ALDH1A1 (0.48) ALDH1A1TDP1CYP3A4TSHRL3MBTL1
SCHEMBL3884739 0.77 LMNA (0.31)
SCHEMBL1447691 0.76 ALDH1A1 (0.39) ALDH1A1TDP1CYP3A4TSHRL3MBTL1
SCHEMBL2532944 0.76
SCHEMBL14812440 0.75
SCHEMBL9213515 0.75 LMNA (0.45) ALDH1A1TDP1CYP3A4TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202322-B2 Resorcinol derivatives SUTTER BAY HOSPITALS (US) 2019-02-12 US claimed
US-20180170846-A1 RESORCINOL DERIVATIVES SUTTER WEST BAY HOSPITALS 2018-06-21 US claimed
US-20130209483-A1 CANNABIDINOID DERIVATIVES SUTTER WEST BAY HOSPITALS (US) 2013-08-15 US claimed
EP-3898625-B1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2024-04-17 EP disclosed
US-20220064158-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2022-03-03 US disclosed
EP-3898625-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY Imperial College Innovations Limited (GB) 2021-10-27 EP disclosed
WO-2020128473-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2020-06-25 WO disclosed
US-10202322-B2 Resorcinol derivatives SUTTER BAY HOSPITALS (US) 2019-02-12 US disclosed
US-20180170846-A1 RESORCINOL DERIVATIVES SUTTER WEST BAY HOSPITALS 2018-06-21 US disclosed
US-9809521-B2 Cannabidinoid derivatives SUTTER WEST BAY HOSPITALS (US) 2017-11-07 US disclosed
US-20160376211-A1 CANNABIDINOID DERIVATIVES SUTTER WEST BAY HOSPITALS 2016-12-29 US disclosed
EP-1296991-B1 SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2013-05-15 EP disclosed
CN-1178960-C Siloxy substituted cocatalyst activators for olefin polymerization 埃克森美孚化学专利公司 2004-12-08 CN disclosed
CN-1172964-C Nitrogen-containing group 13 anionic compound for olefin polymerization ����ɭ���ڻ�ѧר����˾ 2004-10-27 CN disclosed
CN-1437607-A Siloxy substituted cocatalyst activators for olefin polymerization EXXONMOBIL CHEM PATENTS INC (US) 2003-08-20 CN disclosed
CN-1427849-A Nitrogen-Containing group-13 anionic compounds for olefin polymerization EXXONMOBIL CHEM PATENTS INC (US) 2003-07-02 CN disclosed
EP-1296991-A1 SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION ExxonMobil Chemical Patents Inc. (US) 2003-04-02 EP disclosed
EP-1297027-A1 SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION Exxonmobil Chemical Patents Inc. (US) 2003-04-02 EP disclosed
WO-2002000738-A1 SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-01-03 WO disclosed
WO-2002000666-A1 SILOXY SUBSTITUTED COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202322-B2 Resorcinol derivatives CNR1, CNR2, RCOR1 ALDH1A1 1955/4885TDP1 3021/4885CYP3A4 336/4885
US-20220064158-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PLAAT2, PLAAT3, ACAT2 ALDH1A1 4324/4885TDP1 1410/4885CYP3A4 4699/4885
US-20130209483-A1 CANNABIDINOID DERIVATIVES CNR2, CNR1, GPR18 ALDH1A1 3491/4885TDP1 2676/4885CYP3A4 1389/4885
US-20160376211-A1 CANNABIDINOID DERIVATIVES CNR2, CNR1, GPR18 ALDH1A1 3491/4885TDP1 2676/4885CYP3A4 1389/4885
US-20180170846-A1 RESORCINOL DERIVATIVES CNR1, CNR2, RCOR1 ALDH1A1 1955/4885TDP1 3021/4885CYP3A4 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.